SCHEMBL9917431

SCHEMBL9917431

Cc1ccc(Cn2cc3cc([N+](=O)[O-])c(C)cc3n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
DUSP3 P51452 1/20 0.42
MAPT P10636 5/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 2/20 0.41
NFKB1 P19838 1/20 0.41
CASP3 P42574 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
DCTPP1 Q9H773 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9917444 0.91 HDAC6 (0.44) LMNARAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL9917425 0.89 LMNA (0.48) LMNARAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL16418008 0.82 RAB9A (0.44) LMNARAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL9917424 0.79 RAB9A (0.42) LMNARAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL9917443 0.79 HDAC6 (0.46) LMNASMN1; SMN2L3MBTL1MAPTKMT2A
SCHEMBL9917429 0.78 RAB9A (0.41) RAB9ASMN1; SMN2L3MBTL1DUSP3MAPT
SCHEMBL17458975 0.77 LMNA (0.50) LMNARAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL31600432 0.75 MAPT (0.58) LMNARAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL9917423 0.75 RAB9A (0.41) RAB9ASMN1; SMN2L3MBTL1DUSP3MAPT
SCHEMBL16418006 0.72 BRD4 (0.43) LMNASMN1; SMN2L3MBTL1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149463-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) 2015-10-06 US disclosed
US-20150152064-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2015-06-04 US disclosed
US-20150152064-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2015-06-04 US disclosed
US-8940730-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-01-27 US disclosed
US-8940730-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-01-27 US disclosed
US-20120148534-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148534-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION EIF2AK2, NSUN3, NSUN2 LMNA 1328/4885RAB9A 2617/4885SMN1; SMN2 2247/4885
US-20150152064-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION EIF2AK2, NSUN3, NSUN2 LMNA 1328/4885RAB9A 2617/4885SMN1; SMN2 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.